{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T19:48:35Z","timestamp":1725738515803},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00059-019-4800-0","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T14:55:04Z","timestamp":1554216904000},"page":"304-309","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Verschluss des offenen Foramen ovale (PFO) beim kryptogenen Schlaganfall"],"prefix":"10.1007","volume":"44","author":[{"given":"H.-C.","family":"Diener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Knebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"issue":"18","key":"4800_CR1","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJM198805053181802","volume":"318","author":"P Lechat","year":"1988","unstructured":"Lechat P, Mas JL, Lascault G et\u00a0al (1988) Prevalence of patent foramen ovale in patients with stroke. N\u00a0Engl J Med 318(18):1148\u20131152","journal-title":"N Engl J Med"},{"issue":"11","key":"4800_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","volume":"366","author":"AJ Furlan","year":"2012","unstructured":"Furlan AJ, Reisman M, Massaro J et\u00a0al (2012) Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N\u00a0Engl J Med 366(11):991\u2013999","journal-title":"N Engl J Med"},{"issue":"12","key":"4800_CR3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","volume":"368","author":"B Meier","year":"2013","unstructured":"Meier B, Kalesan B, Mattle HP et\u00a0al (2013) Percutaneous closure of patent foramen ovale in cryptogenic embolism. N\u00a0Engl J Med 368(12):1083\u20131091","journal-title":"N Engl J Med"},{"issue":"12","key":"4800_CR4","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","volume":"368","author":"JD Carroll","year":"2013","unstructured":"Carroll JD, Saver JL, Thaler DE et\u00a0al (2013) Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N\u00a0Engl J Med 368(12):1092\u20131100","journal-title":"N Engl J Med"},{"issue":"11","key":"4800_CR5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","volume":"377","author":"JL Mas","year":"2017","unstructured":"Mas JL, Derumeaux G, Guillon B et\u00a0al (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N\u00a0Engl J Med 377(11):1011\u20131021","journal-title":"N Engl J Med"},{"issue":"11","key":"4800_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","volume":"377","author":"JL Saver","year":"2017","unstructured":"Saver JL, Carroll JD, Thaler DE et al (2017) Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N\u00a0Engl J Med 377(11):1022\u20131032","journal-title":"N Engl J Med"},{"issue":"11","key":"4800_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","volume":"377","author":"L Sondergaard","year":"2017","unstructured":"Sondergaard L, Kasner SE, Rhodes JF et\u00a0al (2017) Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N\u00a0Engl J Med 377(11):1033\u20131042","journal-title":"N Engl J Med"},{"issue":"20","key":"4800_CR8","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","volume":"71","author":"PH Lee","year":"2018","unstructured":"Lee PH, Song JK, Kim JS et al (2018) Cryptogenic stroke and high-risk patent foramen Ovale: the DEFENSE-PFO trial. J\u00a0Am Coll Cardiol 71(20):2335\u20132342","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"4800_CR9","doi-asserted-by":"publisher","first-page":"e004282","DOI":"10.1136\/bmjopen-2013-004282","volume":"4","author":"FA Spencer","year":"2014","unstructured":"Spencer FA, Lopes LC, Kennedy SA, Guyatt G (2014) Systematic review of percutaneous closure versus medical therapy in patients with cryptogenic stroke and patent foramen ovale. BMJ Open 4(3):e4282","journal-title":"BMJ Open"},{"issue":"7","key":"4800_CR10","doi-asserted-by":"publisher","first-page":"e023761","DOI":"10.1136\/bmjopen-2018-023761","volume":"8","author":"H Mir","year":"2018","unstructured":"Mir H, Siemieniuk RAC, Ge LC et al (2018) Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a\u00a0systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open 8(7):e23761","journal-title":"BMJ Open"},{"issue":"6","key":"4800_CR11","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1161\/STROKEAHA.117.018153","volume":"49","author":"JL Saver","year":"2018","unstructured":"Saver JL, Mattle HP, Thaler D (2018) Patent foramen ovale closure versus medical therapy for cryptogenic Ischemic stroke: a topical review. Stroke 49(6):1541\u20131548","journal-title":"Stroke"},{"issue":"12","key":"4800_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11910-018-0910-y","volume":"18","author":"H-C Diener","year":"2018","unstructured":"Diener H\u2011C, Gerloff C, Thaler DE, W\u00f6hrle J (2018) Closure of patent foramen ovale and cryptogenic stroke: unresolved issues. Curr Neurol Neurosci Rep 18(12):92","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"13","key":"4800_CR13","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.4244\/EIJ-D-18-00622","volume":"14","author":"C Pristipino","year":"2019","unstructured":"Pristipino C, Sievert H, D\u2019Ascenzo F et\u00a0al (2019) European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. EuroIntervention 14(13):1389\u20131402","journal-title":"EuroIntervention"},{"issue":"2","key":"4800_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1161\/STROKEAHA.117.020030","volume":"49","author":"G Ntaios","year":"2018","unstructured":"Ntaios G, Papavasileiou V, Sagris D et al (2018) Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient Ischemic attack: updated systematic review and Meta-analysis. Stroke 49(2):412\u2013418","journal-title":"Stroke"},{"key":"4800_CR15","doi-asserted-by":"publisher","first-page":"k2515","DOI":"10.1136\/bmj.k2515","volume":"362","author":"T Kuijpers","year":"2018","unstructured":"Kuijpers T, Spencer FA, Siemieniuk RAC et\u00a0al (2018) Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ 362:k2515","journal-title":"BMJ"},{"issue":"7","key":"4800_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1474-4422(18)30167-4","volume":"17","author":"S Mazzucco","year":"2018","unstructured":"Mazzucco S, Li L, Binney L et al (2018) Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a\u00a0population-based study, systematic review, and meta-analysis. Lancet Neurol 17(7):609\u2013617","journal-title":"Lancet Neurol"},{"issue":"7","key":"4800_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1212\/WNL.0b013e3182a08d59","volume":"81","author":"DM Kent","year":"2013","unstructured":"Kent DM, Ruthazer R, Weimar C et al (2013) An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 81(7):619\u2013625","journal-title":"Neurology"},{"issue":"1","key":"4800_CR18","doi-asserted-by":"publisher","first-page":"NP7","DOI":"10.1177\/1747493015607505","volume":"11","author":"D Prefasi","year":"2016","unstructured":"Prefasi D, Martinez-Sanchez P, Fuentes B, Diez-Tejedor E (2016) The utility of the RoPE score in cryptogenic stroke patients \u3008\/=50 years in predicting a\u00a0stroke-related patent foramen ovale. Int J Stroke 11(1):NP7\u2013NP8","journal-title":"Int J Stroke"},{"issue":"24","key":"4800_CR19","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1056\/NEJMoa011503","volume":"345","author":"JL Mas","year":"2001","unstructured":"Mas JL, Arquizan C, Lamy C et\u00a0al (2001) Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N\u00a0Engl J Med 345(24):1740\u20131746","journal-title":"N Engl J Med"},{"issue":"18","key":"4800_CR20","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1093\/eurheartj\/ehy121","volume":"39","author":"Y Ahmad","year":"2018","unstructured":"Ahmad Y, Howard JP, Arnold A et al (2018) Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a\u00a0meta-analysis of randomized controlled trials. Eur Heart\u00a0J 39(18):1638\u20131649","journal-title":"Eur Heart J"},{"key":"4800_CR21","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa022066","volume":"348","author":"S Vermeer","year":"2003","unstructured":"Vermeer S, Prins N, den Heijer T et\u00a0al (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N\u00a0Engl J Med 348:1215\u20131222","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"4800_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000437261","volume":"74","author":"B Lapergue","year":"2015","unstructured":"Lapergue B, Decroix JP, Evrard S et\u00a0al (2015) Diagnostic yield of venous thrombosis and pulmonary embolism by combined CT venography and pulmonary angiography in patients with cryptogenic stroke and patent foramen ovale. Eur Neurol 74(1\u20132):69\u201372","journal-title":"Eur Neurol"},{"issue":"6 Suppl","key":"4800_CR23","doi-asserted-by":"publisher","first-page":"454S","DOI":"10.1378\/chest.08-0658","volume":"133","author":"C Kearon","year":"2008","unstructured":"Kearon C, Kahn SR, Agnelli G et al (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):454S\u2013545S","journal-title":"Chest"},{"issue":"6","key":"4800_CR24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.thromres.2014.03.035","volume":"133","author":"N Kang","year":"2014","unstructured":"Kang N, Sobieraj DM (2014) Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thromb Res 133(6):1145\u20131151","journal-title":"Thromb Res"},{"issue":"10","key":"4800_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00115-018-0609-y","volume":"89","author":"HC Diener","year":"2018","unstructured":"Diener HC, Grau AJ, Baldus S et\u00a0al (2018) Kryptogener Schlaganfall und offenes Formaen ovale: S2e Leirtlinie [Cryptogenic stroke and patent foramen ovale : S2e guidelines]. Nervenarzt 89(10):1143\u20131153","journal-title":"Nervenarzt"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4800-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-019-4800-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4800-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:03:08Z","timestamp":1585699388000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-019-4800-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4800"],"URL":"https:\/\/doi.org\/10.1007\/s00059-019-4800-0","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"2 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"H.-C.\u00a0Diener hat Honorare f\u00fcr Teilnahme an klinischen Studien, Mitarbeit in Advisory Boards und Vortr\u00e4ge erhalten von Abbott, Allergan, AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, BrainsGate, CoAxia, Corimmun, Covidien, Daiichi Sankyo, D\u2011Pharm, Fresenius, GlaxoSmithKline, Janssen-Cilag, Lilly, Lundbeck, Medtronic, MSD, MindFrame, Neurobiological Technologies, Novartis, Novo Nordisk, Paion, Parke-Davis, Pfizer, Portola, Sanofi-Aventis, Schering, Servier, Solvay, St. Jude Medical, Syngis, Tacrelis, Thrombogenics und Wyeth. Forschungsprojekte der Universit\u00e4tsklinik f\u00fcr Neurologie in Essen wurden unterst\u00fctzt von AstraZeneca, GSK, Boehringer Ingelheim, Novartis, Janssen-Cilag und Sanofi-Aventis. Die Universit\u00e4tsklinik f\u00fcr Neurologie hat Forschungsmittel von den folgenden Institutionen erhalten: Deutsche Forschungsgemeinschaft (DFG), Bundesministerium f\u00fcr Bildung und Forschung (BMBF), Europ\u00e4ische Union (EU), National Institutes of Health (NIH), EAST(Early Treatment of Atrial Fibrillation for Stroke Prevention Trial)-AFNET(Atrial Fibrillation Network), Bertelsmann Stiftung und Heinz Nixdorf Stiftung. H.-C. Diener besitzt keine Aktien oder Anteile von Pharma- oder Medizintechnikfirmen und war beteiligt an der Erstellung von Leitlinien der Deutschen Gesellschaft f\u00fcr Neurologie (DGN), der Deutschen Schlaganfall-Gesellschaft (DSG), der European Society of Cardiology (ESC) und der European Heart Rhythm Association (EHRA). F.\u00a0Knebel hat Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards erhalten von Abbott, AstraZeneca, Bracco, Bristol-Myers Squibb, Novartis und besitzt keine Aktien oder Anteile von Pharma- oder Medizintechnikfirmen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}